Drug safety profile of integrase strand transfer inhibitors

Bibliography

• Smit M, Smit C, Cremin I, et al. Could better tolerated HIV drug regimens improve patient outcome? AIDS 2012;26:1953-9
   PubMed Web of Science ®Google Scholar
• Malet I, Calvez V, Marcelin AG. The future of integrase inhibitors of HIV-1. Curr Opin Virol 2012;2:580-7
   Web of Science ®Google Scholar
• Pommier Y, Johnson A, Marchand C. Integrase inhibitors to treat HIV/Aids. Nature Rev Drug Discov 2005;4(3):236-48
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54
   PubMed Web of Science ®Google Scholar
• Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009;49:1441-9
   PubMed Web of Science ®Google Scholar
• Karmon SL, Markowitz M. Next-generation integrase inhibitors : where to after raltegravir? Drugs 2013;73(3):213-28
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Markowitz M, Ratanasuwan W, et al. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). J Acquir Immune Defic Syndr 2012;61(1):73-7
   PubMed Web of Science ®Google Scholar
• Gatell JM, Katlama C, Grinsztejn B, et al. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study. J Acquir Immune Defic Syndr 2010;53(4):456-63
   PubMed Web of Science ®Google Scholar
• Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis 2013;13(7):587-96
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008;83(2):293-9
   PubMed Web of Science ®Google Scholar
• Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses 2013;29(2):256-65
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1 infected patients: final five-year results from STARTMRK. J Acquir Immune Defic Syndr 2013;63(1):77-85
   PubMed Web of Science ®Google Scholar
• DeJesus E, Cohen C, Lennox J, et al. Metabolic profiles and body composition changes in treatment-naive HIV-infected patients treated with raltegravir 400 mg twice-daily vs efavirenz 600 mg each bedtime combination therapy: 96-week follow-up [abstract 720]. 17th Conference on Retroviruses and Opportunistic Infections; 16 – 19 February 2010; San Francisco, California, USA
   Google Scholar
• DeJesus E, Felix J, Vandewalle B, et al. Indirect treatment comparison of efficacy, safety and resistance of EVG/COBI/FTC/TDF (Quad) vs. RAL+FTC/TDF in treatment-naïve HIV patients [abstract P265]. Eleventh International Congress on Drug Therapy in HIV Infection; 11 – 15 November 2012; Glasgow, UK
   Google Scholar
• Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381(9868):735-43
   PubMed Web of Science ®Google Scholar
• Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013;13:927-35
   PubMed Web of Science ®Google Scholar
• Eron JJ, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011;11(12):907-15
   PubMed Web of Science ®Google Scholar
• Kozal MJ, Lupo S, DeJesus E, et al. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. HIV Clin Trials 2012;13(3):119-30
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak A, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013;382(9893):700-8
   PubMed Web of Science ®Google Scholar
• Elion R, Molina J-M, Arribas JR, et al. A randomized phase 3 study comparing once-daily elvitegravir to twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr 2013;63(4):494-7
   PubMed Web of Science ®Google Scholar
• SECOND-LINE Study Group. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet 2013;381(9883):2062-3
   PubMedGoogle Scholar
• Martin A, Moore C, Mallon P, et al. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard Second Line therapy. AIDS 2013;27(15):2403-11
   PubMed Web of Science ®Google Scholar
• Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010;24(11):1697-707
   PubMed Web of Science ®Google Scholar
• Martinez E, D'lbuquerque PM, Llibre JM, et al. Changes of cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012;26(18):2315-26
   PubMed Web of Science ®Google Scholar
• Curran A, Martinez E, Saumoy M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS 2012;26(4):475-81
   PubMed Web of Science ®Google Scholar
• Nguyen A, Calmy A, Delhumeau C, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011;25(12):1481-7
   PubMed Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375(9712):396-407
   PubMed Web of Science ®Google Scholar
• Domingo P, Gutierrez MM, Gallego-Escuredo JM, et al. Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). PLoS One 2014; In Press
   Web of Science ®Google Scholar
• Fabbiani M, Mondi A, Colafigli M, et al. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scand J Infect Dis 2014;46(1):34-45
   PubMed Web of Science ®Google Scholar
• Squires K, Bekker LG, Eron J, et al. Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK study. AIDS Res Hum Retroviruses 2013;29(6):859-70
   PubMed Web of Science ®Google Scholar
• Valnet Rabier MB, Bacquet V, Fleck C, et al. Raltegravir (ISENTRESS®): assessement of 5 years of adverse effects reporting in France. Fundam Clin Pharmacol 2013;27(Suppl 1):102
   Google Scholar
• McAllister J, Read P, McNulty A, et al. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. HIV Med 2014;15(1):13-22
   PubMed Web of Science ®Google Scholar
• Mayer K, Mimiaga M, Gelman M, et al. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012;59(4):354-9
   PubMed Web of Science ®Google Scholar
• Monteiro P, Perez I, Pich J, et al. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study. J Antimicrob Chemother 2013;68(2):404-8
   PubMed Web of Science ®Google Scholar
• Lee FJ, Amin J, Bloch M, et al. Skeletal muscle toxicity associated with raltegravir-based combination anti-retroviral therapy in HIV-infected adults. J Acquir Immune Defic Syndr 2013;62(5):525-33
   PubMed Web of Science ®Google Scholar
• Madeddu G, Menzaghi B, Ricci E, et al. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. AIDS 2012;26(18):2421-3
   PubMedGoogle Scholar
• Yapa HM, Waters L, Rowlands J, et al. The feasibility of switching efavirenz (EFV)-based highly active antiretroviral therapy to raltegravir (RAL)-based therapy in HIV-infected individuals with central nervous system (CNS) toxicity: a phase IV open label pilot study [abstract O22]. BHIVA 19th Annual Conference of the British HIV Association; 16 – 19 April 2013; Manchester, UK
   Google Scholar
• Nishijima T, Gatanaga H, Shimbo T, et al. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial. PLoS One 2013;8(8):e73639
   PubMedGoogle Scholar
• Vispo E, Mena A, Maida I, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2010;65:543-7
   PubMed Web of Science ®Google Scholar
• Lennox JL, DeJesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010;55(1):39-48
   PubMed Web of Science ®Google Scholar
• Pozniak A, Mingrone H, Shuldyakov A, et al. Dolutegravir vs raltegravir in ART-experienced, integrase-naïve subjects: 24-week interim results from SAILING (ING111762) [paper#179LB]. 20th Conference on Retroviruses and Opportinistic Infections; 3 – 6 March 2013; Atlanta, GA
   Google Scholar
• Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, doubleblind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379:2439-48
   PubMed Web of Science ®Google Scholar
• Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013;63(1):96-100
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, doubleblind, phase 3, non-inferiority trial. Lancet 2012;379:2429-38
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013;62(5):483-6
   PubMed Web of Science ®Google Scholar
• Shalit P, Gallant J, Mills A, et al. Long-term tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir DF compared to efavirenz/emtricitabine/tenofovir DF or ritonavir-boosted atazanavir Plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected subjects [abstract H-671]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 10 – 13 September 2013; Denver, CO, USA
   Google Scholar
• Stellbrinka HJ, Reynesb J, Lazzarinc A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013;27:1771-8
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013;369:1807-18
   PubMed Web of Science ®Google Scholar
• Tebas P, Kumar P, Hicks C, et al. 48 week bone marker changes in dolutegravir (DTG; GSK1349572) plus abacavir/lamivudine (ABC/3TC) vs tenofovir/emtricitabine/efavirenz (EFV/TDF/FTC): the SINGLE trial [abstract H-1461]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 10 – 13 September 2013; Denver, CO
   Google Scholar
• Feinberg J, Clotet B, Khuong MA, et al. Once-daily dolutegravir (DTG) is superior to darunavir/ritonavir (DRV/r) in antiretroviral–naive adults: 48 week results from FLAMINGO (ING114915) [abstract H-1464a]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 10 – 13 September 2013; Denver, CO
   Google Scholar
• Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis 2013;207:740-8
   PubMed Web of Science ®Google Scholar
• Nichols G, Lazzarin A, Maggiolo F, et al. Phase 3 assessment of dolutegravir (DTG) 50 mg twice daily (BID) in HIV-1–infected subjects with raltegravir (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: week 24 results of All 183 subjects enrolled [TULBPE19]. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30 – July 3, 2013; Kuala Lumpur, Malaysia
   Google Scholar
• Curtis LD, Min S, Nichols G, et al. Once-daily dolutegravir (DTG; GSK1349572) has a renal safety profile comparable to raltegravir (RAL) and efavirenz in antiretroviral (ART)-naive adults: 48 week results from SPRING-2 (ING113086) and SINGLE (ING114467) [abstract TUPE282]. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30 – July 3 2013; Kuala Lumpur, Malaysia
   Google Scholar
• Mascolini M. Small drop in creatinine clearance with dolutegravir in healthy volunteers. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17 – 20 September 2011; Chicago
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services, October 2013. Available from: http://aidsinfo.nih.gov/contentfiles/AdultARV_INSTIRecommendations.pdf [Last accessed 19 December 2013]
   Google Scholar